SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Net Loss of Significant Expense

The following table presents segment revenue and significant expenses regularly reviewed by the CODM for the three months ended March 31, 2025 and 2024:

	Three Months Ended March 31,
(in thousands)	2025		2024
Royalty revenues	$	202	$	98
Operating expenses
Research and development:
Repibresib (VYN201)	2,577		1,897
VYN202	2,521		1,006
Other segment items*	1,026		805
General and administrative	3,275		3,770
Total operating expenses	9,399		7,478
Operating loss	(9,197)		(7,380)
Other income, net	594		1,139
Loss from continuing operations before income taxes	(8,603)		(6,241)
Income tax expense	—		—
Loss from continuing operations	(8,603)		(6,241)
Loss from discontinued operations, net of income taxes	(8)		(8)
Net loss	$	(8,611)	$	(6,249)

*Other segment items relate to research and development expenses that cannot be directly allocated to one specific product candidate, such as employee-related expenses, consulting, quality control, regulatory, and general IP legal expenses.